In the Real World Study, the Efficacy and Adverse Reactions of Ticagrelor on Ischemic Cerebrovascular Disease
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorQianfoshan Hospital
About this trial
This is a forward-looking, open, one-arm, and real clinical trial world. The researchers plan to recruit at least 50 qualified patients. The main purpose of this study is to establish a population pharmacokinetic model of ticagrelor , explore the correlation between its blood concentration and the events of ischemia and the adverse effects of hemorrhage, and evaluate the effectiveness and safety of ticagrelor in the treatment of ischemic cerebrovascular disease.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Female or male aged ≥ 18 years.
Clinically diagnosed as ischemic cerebrovascular disease.
Take ticagelor for antiplatelet therapy.
Provision of informed consent.
Disqualifiers
Head CT or MRI suggests the presence of intracranial hemorrhagic disease.
People with tumors and other serious systemic diseases.
Allergy to ticagelor.
Trial population
Patients with ischemic cerebrovascular disease must sign written informed consent before collecting blood samples
Trial design
Design model
Other
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Correlation between blood drug concentration and adverse events
Try to find the relationship between pharmacokinetic parameters and adverse events
Time frame
6 monthsSecondary outcomes
1
The incidence of adverse events caused by treatment
In a clinical trial, the probability of an unexpected and adverse medical event that occurs after a patient or clinical subject receives a trial drug, but it does not necessarily have a causal relationship with the treatment.
Time frame
6 months2
NIHSS
NIH stroke scale (NIHSS) to assess the degree of neurological deficit in stroke patients. The score ranges from 0 to 42 points, the higher the score, the more severe the nerve damage. Patients with a baseline assessment of\> 16 points are likely to die, while those with a score of \<6 are likely to recover well; for each additional point, the probability of a good prognosis is reduced by 17%
Time frame
6 months3
mRS
Modified Rankin scale (mRS) is an indicator of the efficacy of functional disability. The score ranges from 0 to 5 points, and the clinical score will be increased to 6 points to indicate death. The higher the score, the more disability the patient is.
Time frame
6 monthsLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: